{
    "clinical_study": {
        "@rank": "137940", 
        "arm_group": [
            {
                "arm_group_label": "Treatment group A", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Treatment B", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The study is being conducted to evaluate the efficacy, safety and tolerability of 2%\n      tofacitinib ointment (20 mg/g) BID (twice daily) in subjects with mild to moderate atopic\n      dermatitis compared to placebo (vehicle) BID for 4 weeks."
        }, 
        "brief_title": "Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema)", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Dermatitis, Atopic", 
            "Eczema, Atopic"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Dermatitis", 
                "Dermatitis, Atopic", 
                "Eczema"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have a clinical diagnosis of atopic dermatitis (also known as atopic eczema) for at\n             least 6 months prior to Day 1 that has been clinically stable for at least 1 month\n             prior to Day 1 and is confirmed to be atopic dermatitis according to the criteria of\n             Hanifin and Rajka.\n\n          -  Have a PGA score of 2 (mild) or 3 (moderate) at Day 1.\n\n          -  Have atopic dermatitis on the head (including face, but excluding hair bearing\n             scalp), neck, trunk (excluding groin and genitals), or limbs (excluding palms and\n             soles) covering at least 2% of total body surface area (BSA) and up to and including\n             10% of total BSA at Day 1\n\n        Exclusion Criteria:\n\n          -  Evidence of certain skin conditions/infections at baseline\n\n          -  Currently have atopic dermatitis on groin, genitals, palm or soles\n\n          -  Have certain laboratory abnormalities at baseline\n\n          -  Females who are pregnant, breastfeeding, or are of childbearing potential not using\n             highly effective contraception"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02001181", 
            "org_study_id": "A3921214"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment group A", 
                "description": "Tofacitinib ointment 20mg/g twice daily (BID) for 4 weeks", 
                "intervention_name": "Tofacitinib ointment 20mg/g", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment B", 
                "description": "Placebo ointment (vehicle) twice daily (BID) for 4 weeks", 
                "intervention_name": "Placebo ointment (Vehicle)", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Atopic Dermatitis", 
            "Atopic Eczema", 
            "Eczema", 
            "topical treatment", 
            "skin diseases", 
            "tofacitinib", 
            "CP-690", 
            "550", 
            "Janus Kinase inhibitor"
        ], 
        "lastchanged_date": "May 15, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921214&StudyName=Tofacitinib%20Ointment%20For%20Atopic%20Dermatitis%20%28Atopic%20Eczema%29"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Peterborough", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "K9J 1Z2"
                    }, 
                    "name": "SKiN Centre for Dermatology"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Richmond Hill", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "L4B 1A5"
                    }, 
                    "name": "The Centre for Dermatology & Cosmetic"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Waterloo", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "N2J 1C4"
                    }, 
                    "name": "K. Papp Clinical Research"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H2K 4L5"
                    }, 
                    "name": "Innovaderm Research Inc."
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Quebec", 
                        "country": "Canada", 
                        "zip": "G1V 4X7"
                    }, 
                    "name": "Centre de Recherche de Dermatologique du Quebec metropolitain"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2a, Multi-Site, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study Of The Pilot Efficacy, Safety, Tolerability, And Pharmacokinetics Of 2% Tofacitinib Ointment In Subjects With Mild To Moderate Atopic Dermatitis", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "percent change from baseline at week 4", 
            "measure": "Eczema Area and Severity Index (EASI)", 
            "safety_issue": "No", 
            "time_frame": "baseline, Week 4"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02001181"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "proportion of subjects with PGA response of \"clear\" or \"almost clear\" at week 4", 
                "measure": "Physician Global Assessment (PGA) of Disease Activity", 
                "safety_issue": "No", 
                "time_frame": "week 4"
            }, 
            {
                "description": "proportion of subjects with PGA response of \"clear\" or \"almost clear\" and >= 2 grade/point improvement from baseline at week 4", 
                "measure": "Physician Global Assessment (PGA) of Disease Activity", 
                "safety_issue": "No", 
                "time_frame": "week 4"
            }, 
            {
                "description": "percent change from baseline in BSA at week 4", 
                "measure": "Body surface ares (BSA)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 4"
            }, 
            {
                "description": "Change from baseline in the EASI clinical sign severity sum score at week 4", 
                "measure": "Eczema area and severity index (EASI)  clinical sign severity sum score", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 4"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}